Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The ADA cohort aims for the systematic and standardized collection of sociodemographic, clinical and neuropsychological data, during 2 visits (inclusion and 12 months), from patients suffering from the co-occurrence of ADHD (Attention Deficit Hyperactivity Disorder) and addiction(s), in addition to the treatment as usual adapted to each situation.
Information on the study and diagnosis of ADHD will be carried out during a medical evaluation consultation, as part of routine care.
The two research visits (inclusion and at 12 months) will be added by the research and will each include:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Neuropsychological assessment | Other | Determination of the neuropsychological profile |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Patients suffering from the co-occurrence of ADHD and addiction(s) | Other | All eligible patients over 18 years, presenting both a diagnosis of ADHD and a diagnosis of at least one addictive disorder (SUD, AUD (Alcohol Use Disorder) and/ or behavioral addiction), starting care in one of the three participating centers, and meeting the indication for treatment with MPH according to European recommendations (J. J. S. Kooij et al., 2019) |
| Measure | Description | Time Frame |
|---|---|---|
| Functional impairment | Weiss Functional Impairment Rating Scale (WFIRS-S) (scores of the 7 domains and total score) | Inclusion and 12-month follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| Type and severity of ADHD | Diagnostiscal Interview Voor Attention deficit hyperactivity disorder (DIVA-5) | Inclusion |
| Symptoms of ADHD | Adult ADHD Self-Report Scale Symptom Checklist (ASRS-1.1) (inattention and hyperactivity/impulsivity scores) |
Not provided
Inclusion Criteria :
Exclusion Criteria :
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Clémence CABELGUEN, PH | Contact | 33 2 40 84 61 16 | clemence.cabelguen@chu-nantes.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nantes University Hospital | Recruiting | Nantes | Loire-Atlantique | 44093 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001289 | Attention Deficit Disorder with Hyperactivity |
| D013035 | Spasm |
| D001523 | Mental Disorders |
| ID | Term |
|---|---|
| D019958 | Attention Deficit and Disruptive Behavior Disorders |
| D065886 | Neurodevelopmental Disorders |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
Not provided
Not provided
Cohort
Not provided
Not provided
Not provided
Not provided
|
| Inclusion and 12-month follow-up |
| Addictive disorders - substance use disorders (including tobacco, alcohol and other substances) | Mini International Neuropsychiatric Interview- Simplified for Diagnostic and Statistical Manual (DSM)-5 (MINI-S) | Inclusion and 12-month follow-up |
| Addictive disorders - gambling disorder | National Opinion research center DSM Screen for gambling problems (NODS) | Inclusion and 12-month follow-up |
| Addictive disorders - sex addiction | Structured interview adapted from the NODS to explore the diagnostic criteria proposed by Carnes et al in 2012 | Inclusion and 12-month follow-up |
| Addictive disorders - gambling disorder | Structured interview adapted from the NODS to explore the diagnostic criteria proposed in the third section of the DSM-5 for the Internet gaming disorder | Inclusion and 12-month follow-up |
| Addictive disorders - eating addiction | Yale Food Addiction Scale (YFAS 2.0) | Inclusion and 12-month follow-up |
| Psychiatric disorders | MINI-S | Inclusion and 12-month follow-up |
| Neuropsychological profile - selective attention | D2-R test (CCT standard score, E% standard score and CC standard score) | Inclusion and 12-month follow-up |
| Neuropsychological profile - short-term and working memory | Digit memory test (standardized scores of numbers of items correctly recalled (direct order, indirect order, ascending order, total), span sizes (direct order, indirect order, ascending order)) | Inclusion and 12-month follow-up |
| Neuropsychological profile - inhibition | Stroop test (standardized execution times (naming condition, interference condition), standardized numbers of uncorrected errors (naming condition, interference condition), and standardized interference score) | Inclusion and 12-month follow-up |
| Neuropsychological profile - spontaneous flexibility | Verbal fluency test (standardized scores for the number of words cited and the number of errors, in both conditions (literal and categorical)) | Inclusion and 12-month follow-up |
| Neuropsychological profile - planning | Zoo test (total profile score) | Inclusion and 12-month follow-up |
| Psychopathological profile - impulsivity | Urgency, Premeditation (lack of), Perseverance (lack of), Sensation seeking impulsivity behavior scale (UPPS-P) (5 scores) | Inclusion and 12-month follow-up |
| Psychopathological profile - emotional dysregulation | Difficulties in Emotion Regulation Scale (DERS-16) (5 scores and total score) | Inclusion and 12-month follow-up |
| Psychopathological profile - sensorial profile | Sensory profile of Winnie Dunn - adult version (category and raw scores in the 4 quadrants) | Inclusion and 12-month follow-up |
| Psychopathological profile - self-esteem | Rosenberg Self-Esteem Scale (RSES) (total score) | Inclusion and 12-month follow-up |
| Quality of life survey | World Health Organization Quality Of Life (WHOQoL-26) (4 scores) | Inclusion and 12-month follow-up |
| Care received | Effective implementation of treatment with MPH (yes/no) or atomoxetine (yes/no), If no, reasons for not implementing it (for MPH), Care provided (Cognitive remediation / behavioral and cognitive therapy / psychoeducation / other psychosocial intervention (details) / other drug treatment), Reported compliance and misuse for MPH and atomoxetine, Reported compliance for non-drug care, Tolerance: numerical scale from 0 to 10 for the evaluation of the main adverse effects (for MPH and for atomoxetine). | 12-month follow-up |
| Personal and family medical history | List of somatic, psychiatric and addictive disorders for personal history, list of psychiatric and addictive disorders for family history | Inclusion |
| Sociodemographics | Age, gender, level of education, professional status, number of children | Inclusion |
| CHRU de Brest | Recruiting | Brest | 29000 | France |
|
| CHRU de Tours | Recruiting | Tours | 37000 | France |
|
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |